Researchers at the German Centre for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of heart failure that has so far been difficult to treat. Prof. Johannes Backs, ...

Game Changers in Nephrology' was the theme of the 62nd European Renal Association (ERA) Congress, held in Vienna, ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary endpoints in the BaxHTN Phase III trial, effectively lowering blood pressure ...

The obstructive sleep apnea (OSA) market is being propelled by the rapid evolution of early detection and diagnostic tools. Technologies like home sl ...

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival and reduce hospitalizations, but the company sees promise in data from an ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 program. The trial showed that anselamimab, a light chain depleter ...

David’s blood pressure was dangerously high until he received specialized care and renal denervation at BIDMC’s Complex Hypertension Clinic. Read his story.

CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) ...

CVRx, Inc. (NASDAQ: CVRX) ('CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare ...